regn5458
regeneron pharmaceuticals
regn5458 bcmaxcd3 bispecific ab in heavily pretreated patients; well tolerated with low rate of crs, overall response 75% at highest dose. #ims2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.